SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market cap as key catalysts for significant potential upside. The community is actively discussing the possibility of a major price breakout, with many drawing comparisons to previous market cycles and pinning hopes on upcoming exchange listings or an broader resurgence in the NFT sector.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for the community due to renewed institutional interest and a wave of activity surrounding its potential in real-world asset (RWA) tokenization and post-quantum security research. Investors are actively debating the long-term viability of the project, weighing concerns over its historical price performance against optimism that new governance developments and potential regulatory clarity will drive future utility.

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Eton Pharmaceuticals Inc

Eton Pharmaceuticals is currently trending due to its recent FDA approval for DESMODA, a milestone that community members view as a significant step in the company's evolution from a biotech hopeful to a revenue-generating commercial player. The community is actively discussing the stock's potential as an undervalued "hidden gem," citing strong recent financial performance, successful portfolio expansion, and an upcoming earnings report as key drivers for potential long-term growth.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is seeing heightened trader attention as the community debates its potential as a high-performance Layer 1 alternative to established networks like Ethereum and Solana. Discussions are currently dominated by a mix of long-term optimism regarding its ecosystem growth and staking utility versus concerns over recent price volatility and token distribution schedules.

Maul Coin

Maul Coin is currently trending as its community actively rallies to drive visibility and growth, focusing on aggressive social media promotion and a "Maul" mentality to gain traction without a traditional marketing budget. The discourse is heavily centered on the active presence of the developer, building a grassroots movement, and the collective push to reach significant milestones like a dollar-based valuation and increased watcher counts on trading platforms.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing a surge in community interest driven by anticipation of upcoming cannabis-related catalysts and the approach of annual industry milestones. Supporters are actively highlighting the project's organic growth and long-term vision, positioning it as a culture-driven alternative to traditional cannabis stocks.

Taseko Mines Ltd. operates as a mining company which engages in the acquisition, development, and operation of mineral deposits. It holds interest in the Gibraltar, Florence Copper, Aley Niobium, Yellowhead, New Prosperity, and Harmony projects. The company was founded on April 15, 1966 and is headquartered in Vancouver, Canada.

Taseko Mines Ltd.

Taseko Mines is drawing significant investor interest as it nears the commercial launch of its Florence Copper project in Arizona, which is expected to double production capacity and establish the company as a key domestic copper source. The community remains focused on the project's ability to drive long-term cash flow, while broader discourse highlights the stock's leverage to rising global copper demand from AI, electrification, and supply constraints.

BENQI is a decentralized non-custodial liquidity market protocol, built on Avalanche. The protocol enables users to effortlessly lend, borrow, and earn interest with their digital assets. Depositors providing liquidity to the protocol may earn passive income, while borrowers are able to borrow in an over-collateralized manner.

Benqi Finance

Benqi Finance is seeing significant community discussion driven by its status as a major DeFi project on the Avalanche network, with investors closely watching its total value locked and potential for real-world asset integration. While some holders express frustration over recent price volatility and accumulation struggles, many participants remain optimistic about its long-term utility and ecosystem growth alongside AVAX.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is currently attracting significant attention as investors react to a planned 20-25% reduction in its global workforce, a move widely interpreted as a cost-cutting measure to prepare for a lower oil price environment. The community is actively debating the stock's future amid this restructuring, with many investors weighing the company's long-term operational resilience against broader sector headwinds and ongoing volatility in commodity markets.

LendingClub Corp. engages in the operations of digital marketplace banks. It operates through the LendingClub Bank and LendingClub Corporation (Parent Only) segments. The LendingClub Bank segment is involved in the provision of full complement of financial products and solutions, loans, leases, and deposits. The LendingClub Corporation (Parent Only) segment includes the holding company legal entity. The company was founded by Renaud Laplanche and Soulaiman Htite on October 2, 2006 and is headquartered in San Francisco, CA.

LendingClub Corp

LendingClub is generating significant investor attention as market participants debate its role as a conservative value-play within the fintech sector, specifically contrasting its risk-mitigated balance sheet and institutional backing against higher-growth, more volatile peers. The discourse is heavily centered on upcoming earnings and strategic catalysts, with community sentiment divided between those optimistic about its long-term stability and those frustrated by its perceived lack of aggressive marketing and slow-moving brand evolution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Microcap MedTech Moving on U.S. Clinical Milestone

Advancements in diabetes technology continue to accelerate as companies race to improve patient outcomes and quality of life. Continuous glucose monitoring (CGM) has become one of the fastest-growing segments in healthcare, but limitations around wearable devices, sensor longevity, and accuracy still leave room for innovation. The next frontier may lie in implantable solutions designed to deliver more precise, real-time data without the burden of external hardware.Shares of Glucotrack, Inc. (NASDAQ: GCTK) are climbing sharply Friday morning after the company announced it is preparing to ...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

<ul class="summary-bullets"><li>Glucotrack stated that the company completed its first‑in‑human study in Brazil in 2025 and initiated a follow-up of its study in Australia.</li><li>The company stated that it has built a dual-source U.S. manufacturing strategy with two qualified contract manufacturing partners.</li><li>Glucotrack stated that its first in-human trial met all its primary and secondary endpoints, with a 99% data capture rate.</li></ul>Glucotrack Inc. (GCTK) shares soared more than 26% in Friday’s opening trade after the company announced that it is in a position to file an Investigational Device Exemption (IDE) for its glucose monitoring technology in the second quarter (Q2) with the U.S. Food and Drug Administration.Glucotrack cited critical operational milestones achieved by the company in developing its continuous blood glucose monitoring (CBGM) technology.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/GCTK">Glucotrack</a> trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">Glucotrack Lists 2025 Milestones</h2>Glucotrack stated that the company completed its first‑in‑human study in Brazil in 2025 and initiated a follow-up of its study in Australia. It said that these updates allow the company to advance toward its clinical program in the U.S.“In 2025, we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology and strengthening Glucotrack’s foundation,” said Glucotrack CEO Paul V Goode.Goode added that Glucotrack has also completed extensive U.S. market research across patients and multiple healthcare provider segments. He noted that CBGM is among the fastest-growing segments in the global diabetes market, which remains among the largest in the healthcare industry.The company stated that it has built a dual-source U.S. manufacturing strategy with two qualified contract manufacturing partners, while also identifying a pathway with a compelling economic profile.<h2 class="st-heading-2">In-Human Study Shows Consistent Testing Performance, Says Glucotrack</h2>Glucotrack said that its first in-human study, which was completed in the first quarter (Q1), showed consistent testing performance. The company stated that the trial met all its primary and secondary endpoints, with a 99% data capture rate and a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs.Glucotrack’s implantable CBGM measures glucose from blood rather than interstitial fluid, thereby eliminating the lag time associated with traditional continuous glucose monitoring systems.<a href="https://stocktwits.com/symbol/GCTK">GCTK stock</a> is down 64% year-to-date and 90% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/huang-nvidia-200-rubin-pods-weekly-wolfe-120-billion-pod-sales-2027-revenue-estimate/cZ3HRwWRIlw">Nvidia CEO Huang’s 200 Rubin Pods A Week Claim Sparks Debate – Here's Why Analysts Aren't Buying The Math</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GCTK Stock Is Soaring Today — What Is Fueling The Surge?

Glucotrack said it has achieved critical operational milestones in developing its continuous blood glucose monitoring technology.

Equity

<ul class="summary-bullets"><li>The patents issued cover critical aspects of Glucotrack’s implantable CBGM technology.</li><li>Unlike conventional CGM systems that sample glucose from interstitial fluid, Glucotrack’s device measures glucose directly from blood.</li><li>The long-term, fully implantable design offers more convenient option for diabetes management.</li></ul>Glucotrack, Inc. (GCTK) announced on Thursday that it has secured three new U.S. patents for its continuous blood glucose monitoring (CBGM) platform.&nbsp;The patents are expected to boost the company’s intellectual property portfolio as it moves its long-term implantable monitoring system closer to commercialization.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GCTK">Glucotrack stock</a> traded over 12% higher in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">New Patents Strengthen IP</h2>The US Patent and Trademark Office issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258, covering critical aspects of Glucotrack’s implantable CBGM technology.The patents protect innovations in sensor chemistry, intravascular lead design, and low-power electronics, all integral to the company’s implantable system.On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day and message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Clinical And Practical Significance</h2>Unlike conventional CGM systems that sample glucose from interstitial fluid, Glucotrack’s device measures glucose directly from blood. This approach is expected to provide near real-time readings, eliminating the lag commonly seen with subcutaneous sensors.&nbsp;<blockquote>“Securing our intellectual property is fundamental to our strategy as we advance our fully implantable, long-term sensor through further clinical testing and toward commercialization.”-Paul V. Goode, President and CEO, Glucotrack</blockquote>The long-term, fully implantable design also aims to reduce patient burden and improve adherence, offering a potentially more convenient option for diabetes management.Glucotrack’s CBGM is a fully implantable device that tracks blood sugar continuously for up to three years. It does not require any wearable parts on the body and needs very little calibration.&nbsp;GCTK stock has declined by over 97% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-guts-stock-fell-revita-post-glp1-data/cmyig4sR4KA">Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A young girl suffering from diabetes type 1, squeezes air bubbles out of her catheter.

Why Did Glucotrack Stock Surge 12% Pre-Market Today?

The company has received patents for its continuous blood glucose monitoring system.

Glucotrack Inc. (GCTK), a medical technology company specializing in diabetes management solutions, attracted significant investor interest after its shares rose by over 144% on Friday afternoon.&nbsp;On Thursday, the company announced a new financing arrangement with Sixth Borough Capital Fund LP. This agreement could provide the company with up to $20 million in equity capital over the next two years, depending on various regulatory and market conditions.On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/GCTK">Glucotrack stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume levels also shifted to ‘extremely high’ from ‘low’ levels in the last 24 hours.<figure class="image"><img style="aspect-ratio:942/113;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_12_133920_png_26d362bae8.webp" alt="GCTK’s Sentiment Meter and Message Volume as of 01:30 p.m. ET on Sep. 12, 2025 | Source: Stocktwits" width="942" height="113"><figcaption>GCTK’s Sentiment Meter and Message Volume as of 01:30 p.m. ET on Sep. 12, 2025 | Source: Stocktwits</figcaption></figure>The stock experienced a 1,800% surge in user message count as of Friday morning. Stocktwits users commended the investment move.&nbsp;<stembedurl>https://stocktwits.com/HUBC1/message/628487656</stembedurl><stembedurl>https://stocktwits.com/ArdentInvestor/message/628487338</stembedurl>The deal includes a purchase agreement and a related registration rights agreement. The agreement grants Glucotrack the right, but not the obligation, to issue and sell shares of its common stock valued at up to $20 million. This offering can be executed incrementally, at the company's discretion, within a 24-month window following the commencement date.This financing vehicle provides Glucotrack with a flexible means to raise capital when needed, enabling it to support product development, commercialization, or general operations.&nbsp;For the second quarter, the company’s net loss increased to $4.75 million, compared to a loss of $4.48 million in the same period last year. Cash and equivalents as of June 30 totaled $9.5 million.&nbsp;Glucotrack stock has lost over 97% of its value year-to-date and 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/opendoor-chairman-keith-rabois-plans-massive-layoffs/chw8v8XRdDA">Opendoor Chairman Keith Rabois Plans Massive Layoffs: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Glucotrack Stock Just Rose Over 123% Today: Here’s An Important Update

Glucotrack announced a new financing arrangement with Sixth Borough Capital Fund LP on Thursday.

Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among healthcare names on Stocktwits.GlucoTrack (GCTK)GlucoTrack posted the highest increase in retail chatter, with message volume surging 3,700% over the past seven days. As of late Sunday, sentiment remained ‘bullish’ among retail traders.On July 8, the company announced the repurchase of over 90% of its Series A Warrants, funded with cash on hand.&nbsp;The move followed last month’s disclosure of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glucotrack-announces-positive-results-from-implantable-blood-glucose-monitor-study/chmJoJwRREo">positive results</a> from its first-in-human clinical study of its continuous blood glucose monitor (CBGM).The implantable device demonstrated 99% data capture, strong accuracy, and no serious adverse events. Designed for a three-year lifespan, the CBGM measures blood glucose directly, not interstitial fluid, and requires no on-body wearable.&nbsp;A long-term feasibility study is expected to launch in Q3 2025.<a href="https://stocktwits.com/symbol/GCTK">GCTK’s stock</a> has declined 98.5% so far in 2025.Sarepta Therapeutics (SRPT)Sarepta saw a 1,991% increase in message volume over the past week, with sentiment remaining ‘extremely bullish’ as of late Sunday, despite mounting regulatory concerns.On July 19, shares plunged over 26% in midday trading after FDA Commissioner Marty Makary said the agency is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-taking-a-hard-look-to-at-whether-sarepta-gene-therapy-elevidys-should-remain-on-the-market/ch8kDByR5qt">“taking a hard look”</a> at whether Sarepta’s gene therapy, Elevidys, should stay on the market.The company disclosed a third patient death on July 18, involving a 51-year-old participant in a limb-girdle muscular dystrophy trial using a similar viral vector to Elevidys. Two earlier deaths were already under FDA investigation. Reuters reported the agency plans to request a voluntary halt to Elevidys' shipments.Amid the fallout,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">analysts criticized Sarepta</a> for not disclosing the fatality earlier, particularly during a recent business update where it announced a 500-job layoff and $400 million in cost cuts.&nbsp;The company has since paused shipments to non-ambulatory patients and&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-surges-after-hours-as-it-slashes-500-jobs-amid-fda-black-box-warning-for-gene-therapy-retail-eyes-rebound/ch8KR0HR5oM">agreed to a black box warning</a> for Elevidys, citing the risk of acute liver failure.<a href="https://stocktwits.com/symbol/SRPT">SRPT’s stock</a> has declined 88.7% so far in 2025.TNF Pharmaceuticals (TNFA)TNF Pharma recorded a 1,900% rise in message volume over the past seven days on Stocktwits, with sentiment labeled ‘extremely bullish’ as of late Sunday.Although there was no specific news catalyst driving the buzz last week, the momentum has been strong since last month when TNFA announced a Compassionate Use collaboration with the DADA2 Foundation to study isomyosamine as a treatment for DADA2, a rare pediatric autoinflammatory disorder.In April,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tnf-pharmaceuticals-to-use-ai-to-recruit-patients/chQSz8ARbXp">TNFA partnered with Renova Health</a> to apply AI and machine learning to optimize patient recruitment. The company is analyzing data from 30,000 patients to identify high-risk cohorts, particularly for interventions related to inflammation and side effects of GLP-1 therapy.TNFA’s pipeline includes two drug platforms: isomyosamine, which regulates inflammatory pathways, and Supera-CBD, which targets chronic pain, addiction, and epilepsy.<a href="https://stocktwits.com/symbol/TNFA">TNFA’s stock</a> has declined 92.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-stealthily-hiked-prices-on-everyday-essentials-as-trump-tariffs-bit-report/ch8qvlTR5Ae">Amazon Stealthily Hiked Prices On Everyday Essentials As Trump Tariffs Bit: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GlucoTrack (GCTK), Sarepta Therapeutics (SRPT), and TNF Pharmaceuticals (TNFA) recorded the highest increases in message volume among healthcare names on Stocktwits. (Photo credit: Getty Images)

GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why

GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny.

Shares of Glucotrack, Inc. (GCTK) traded 32% higher on Wednesday afternoon after the company announced that its first-in-human clinical study for its investigational continuous blood glucose monitor (CBGM) yielded positive results.The medical device company’s CBGM demonstrated excellent accuracy, a 99% data capture rate, and no procedure or device-related serious adverse events, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://glucotrack.com/glucotrack-and-onetwo-analytics-present-positive-final-results-of-first-in-human-study-for-continuous-blood-glucose-monitor-at-american-diabetes-associations-85th-scientific-sessions/">said</a>.Glucotrack’s CBGM is a long-term, implantable system that continually measures glucose from blood rather than interstitial fluid with a sensor designed for a 3-year life and no on-body wearable component.It aims to eliminate the lag time associated with traditional continuous glucose monitoring systems and is connected to subcutaneous electronics that communicate with a mobile application.The in-human study for the CBGM was conducted between Dec. 13, 2024, and Jan. 31, 2025, and included ten participants with either Type 1 or Type 2 diabetes who were on intensive insulin therapy.The insertion and removal procedures were performed by interventional cardiologists.Following the device placement, each participant underwent inpatient observation for 4 days. During this period, frequent blood sampling and glucose tolerance tests were conducted to assess device performance.The system remained in place throughout the study period and was removed successfully at study completion, with patients then followed for 7 days post-removal.Glucotrack now expects to initiate a long-term early feasibility study in Q3 2025, which will evaluate safety and performance of the monitor over an extended period.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GCTK">GCTK</a> soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours to its highest levels in 3 months while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_25_at_12_52_09_PM_png_991ddcc4e4.webp" alt="GCTK's Sentiment Meter and Message Volume as of 12:50 p.m. ET on June 25, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>GCTK's Sentiment Meter and Message Volume as of 12:50 p.m. ET on June 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for Glucotrack being approached by big pharmaceutical companies for either purchase or partnerships following the news.<stembedurl>https://stocktwits.com/Barrister/message/618976594</stembedurl>GCTK stock is down by about 98% this year and has erased nearly all of its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-stock-slumps-after-fda-opens-probe-into-patient-death-analyst-sounds-alarm/chmJnVnRREn">Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A woman holds an insulin pen with an exposed injection needle. Photo: Hannes P. Albert/dpa (Photo by Hannes P Albert/picture alliance via Getty Images)

Glucotrack Announces Positive Results From Its Implantable Blood Glucose Monitor Study: Retail Sentiment Hits 3-Month High

The company’s continuous blood glucose monitor demonstrated excellent accuracy, a 99% data capture rate, and no procedure or device-related serious adverse events, the company said.

Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

GCTK
GlucoTrack Inc

Feed

News

Sentiment

Fundamentals

Info

Latest GCTK News

GCTKGlucoTrack Inc